Abstract
Background: specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodgkin’s Lymphoma) are limited, as well as prophylactic antiviral therapy for B-NHL patients with HBV infection who are receiving anticancer chemotherapy. This study aims to investigate the association between HBV infection and B-NHL, and to evaluate the effect of prophylactic antiviral therapy for HBV-infected B-NHL patients. Study design: A retrospective, case-control study was performed. The study group included 420 patients with B-NHL who were consecutively diagnosed from May 2003 to October 2013 (age range, 14 - 71 years), and the control group included 1280 Chinese residents in Guangxi who participated in the Health Survey (age range, 18 - 74 years). We compared the prevalence rate of HBV infection and clinic-pathologic characteristics between the two groups. The prevalence rate of HBV infection in our study was 34.7% (146/420), higher than the prevalence rate of 13.9% (178/1280) in the general population (P < 0.001). Among 146 B-NHL patients who received anticancer chemotherapy, 104 patients (71.2%) received prophylactic antiviral therapy. Conclusion: This study provides evidence that HBV may play an important role in development of B-NHL. Entecavir maybe the better antiviral drugs than Lamivudine, and antiviral therapy is maintained more than 6 months that maybe the optimal duration of prophylactic antiviral therapy. But further investigation should be conducted for determination of optimal duration and monitoring of antiviral therapy.
Highlights
Hepatitis B virus (HBV) was discovered in 1966 [1], which infected 350 million people worldwide [2]
It has been proposed that hepatitis B virus (HBV) may be an etiologic agent of Non-Hodgkin’s Lymphoma (NHL) [15]-[17], but relatively few studies have investigated the association between HBV infection and B-NHL
All of 420 patients were diagnosed with B-NHL, 146 patients were positive for HBV surface antigen (HBsAg)
Summary
Hepatitis B virus (HBV) was discovered in 1966 [1], which infected 350 million people worldwide [2]. It leads to 340,000 liver cancer cases and 500,000 to 1.2 million liver-related deaths each year [2] [3]. Previous studies have demonstrated an association between hepatitis C virus (HCV) infection and B-NHL [13] [14]. It has been proposed that hepatitis B virus (HBV) may be an etiologic agent of Non-Hodgkin’s Lymphoma (NHL) [15]-[17], but relatively few studies have investigated the association between HBV infection and B-NHL
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
